Monopar Therapeutics Inc. (MNPR)

NASDAQ: MNPR · USD

$73.1

+1.26 (+1.8%)· Recorded snapshot

Market cap	490.7M
Net income (ttm)	-17.8M
EPS (ttm)	-$2.18
Shares out	6.7M
Volume	177,125
Beta	1.51

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -17.8M
EPS (ttm): -$2.18
Market cap: 490.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ホールド

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-19.5

P25 n/aP50 n/aP75 n/a

ROIC-15.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All MNPR indicators

Market & fundamental data

Available fields

179

Groups with data

Currency

USD

Showing 179 of 179 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001645469
Company name	Monopar Therapeutics Inc.
Country	United States
Country code	US
CUSIP number	61023L207
Earnings date	2026-11-12
Earnings time	bmo
Employees	22
Employees change	6
Employees growth	37.5%
Enterprise value	$356.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2019-12-19
Is primary listing	Yes
Is SPAC	No
ISIN number	US61023L2079
Last 10-K release date	2026-03-27
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split date	2024-08-13
Last stock split type	Reverse
Market cap	$490.7M
Market cap category	Small-Cap
Next earnings date	2026-11-12
Options	No
Price	$73.10
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	MNPR
U.S. state	Illinois
Website	https://www.monopartx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-2.98%
FCF / EV yield	-3.61%
FCF yield	-2.58%
Forward EV/Sales	245.49x
Forward P/S	343.08x
P/B ratio	3.69x
Price / tangible book value	3.6x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-811,125
ROA	-14.64%
ROA (5Y)	-32.69%
ROCE	-16.89%
ROE	-19.5%
ROE (5Y)	-59.57%
ROIC	-15.08%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-22.1M
EPS	$-2.18
FCF per share	$-1.81
Financing cash flow	$91.2M
Free cash flow	$-12.2M
Free cash flow minus SBC	$-17.5M
Investing cash flow	$-65.8M
Net cash flow	$13.3M
Net income	$-17.8M
Operating cash flow minus SBC	$-17.5M
Operating income	$-22.1M
Stock-based compensation	$5.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$19.50
Debt / equity	0
Long-term assets	$215,120
Long-term liabilities	$107,828
Net cash (debt)	$134.1M
Net cash / market cap	28.45%
Net cash growth	152.36%
Net debt / equity	-1.02
Piotroski F-Score	1
Property, plant and equipment	$215,120
Shareholders' equity	$130.9M
Tangible book value	$130.9M
Tangible book value per share	$19.50
Total assets	$135M
Total cash	$134.3M
Total debt	$205,663
Total liabilities	$4.1M
WACC	12.56%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$134.8M
Current liabilities	$4M
Current ratio	33.56
Net working capital	$-3.5M
Quick ratio	33.44
Working capital	$130.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-45.84%
Dividend yield	0%
Shareholder yield	-45.84%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$82.78
1D price change	1.75%
1M price change	-15.81%
1M total return	-15.81%
1W price change	-3.33%
1W total return	-3.33%
1Y price change	-11.67%
1Y return CAGR	-11.68%
1Y total return	-11.67%
20-day SMA	$74.96
200-day SMA	$77.20
3M price change	-34.96%
3M total return	-34.96%
3Y price change	3,020%
3Y return CAGR	214.73%
3Y total return	3,020%
50-day SMA	$92.90
50-day SMA vs 200-day SMA	50over200
52-week high	$124.82
52-week high date	2026-08-06
52-week low	$50.07
52-week low date	2026-04-29
5Y price change	187.04%
5Y return CAGR	23.48%
5Y total return	187.04%
6M price change	32.84%
6M total return	32.84%
All-time high	$240.00
All-time high date	2019-12-20
All-time low	$1.37
All-time low date	2023-11-27
Average true range (ATR)	$3.99
Average volume	138.5K
Beta (1Y)	0.58
Beta (2Y)	1.08
Beta (5Y)	1.51
Change from 52-week high	-41.44%
Change from 52-week low	46%
Change from all-time high	-70.1%
Change from all-time low	5,137.96%
Change from open	1.32%
Day's gap	0.43%
Dollar volume	$12.9M
High price	$73.10
Low price	$70.15
Monthly RSI	54.96
Open price	$72.15
Position in 52-week range	100%
Premarket change	0.31%
Premarket close	$71.84
Premarket price	$72.06
Previous close	$71.84
Price vs 150-day SMA	-13.31%
Price vs 20-day SMA	-4.27%
Price vs 200-day SMA	-7.05%
Price vs 50-day SMA	-22.75%
Relative volume	1.28
Return from IPO open	68.22%
Return from IPO price	777.88%
RSI	33.8
Sharpe ratio	0.04
Sharpe ratio (3Y)	0.88
Sharpe ratio (5Y)	0.55
Sortino ratio	0.17
Sortino ratio (3Y)	4.63
Sortino ratio (5Y)	2.42
Volume	177.1K
Weekly RSI	42.15
YTD price change	9.89%
YTD total return	9.89%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4.5M
Float percentage	66.56%
Shares change (QoQ)	0.08%
Shares change (YoY)	45.84%
Shares held by insiders	7.25%
Shares held by institutions	82.9%
Shares outstanding	6.7M
Short % of float	24.31%
Short % of shares	16.18%
Short ratio	7.2 days

Deeper analysis on MNPR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this MNPR report

Is a complete MNPR research report available?

No complete published report is available for Monopar Therapeutics Inc. (MNPR) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Monopar Therapeutics Inc. (MNPR)

Price

Financial snapshot

Fair-value bridge

Latest news · MNPR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All MNPR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on MNPR

Frequently asked questions